IDM Pharma Reports 2008 Financi...(TEMENTS OF OPERATIONS ...)

Date:3/31/2009

TEMENTS OF OPERATIONS (unaudited) Quarter Ended Twelve Months Ended December 31, December 31, 2008 2007 2008 2007 Revenues: Related party revenue $- $5,252,000 $2,401,000 $14,246,000 Research grants and contract revenue (44,000) - 400,000 55,000 License fees, milestones and other revenues 334,000 299,000 346,000 329,000 Total revenues 290,000 5,551,000 3,147,000 14,630,000 Costs and expenses: Research and development 962,000 5,212,000 11,161,000 22,339,000 Selling and marketing 654,000 576,000 1,099,000 1,024,000 General and administrative 2,394,000 2,319,000 8,987,000 11,535,000 Restructuring (260,000) 1,092,000 3,472,000 1,092,000 Contract settlement income from related party - - (5,652,000) - Total costs and expenses 3,750,000 9,199,000 19,067,000 35,990,000 Loss from operations (3,460,000) (3,648,000) (15,920,000) (21,360,000) Interest income 98,000 360,000 722,000 1,118,000 Interest expense related to warrants 1,566,000 1,053,000 (3,072,000) 3,878,000 Other expenses, net 4,000 23,000 4,000 - Foreign exchange gain (loss) 86,000 (381,000) (95,000) (1,680,000) Loss before income tax (1,706,000) (2,593,000) (18,361,000) (18,044,000) Income tax expense (151,000) (89,000) (245,000) (306,
'/>"/>

SOURCE IDM Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results